Home › Companies › Fate Therapeutics, Inc. › 2025-2026

Fate Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Fate Therapeutics, Inc.’s Form 8-K, filed 2026-06-15 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Ballot items
140Asset managers
900Fund votes
2026-06-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Fate Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Fate Therapeutics, Inc.

These tallies are Fate Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-15 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Fate Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Robert S. Epstein, M.D., M.S.	59,332,820	--	--	1,717,842	26,083,760	Majority: yes
Elect Director: Karin Jooss, Ph.D.	59,655,584	--	--	1,395,078	26,083,760	Majority: yes
Elect Director: Laura J. Hamill	60,850,004	--	--	200,658	26,083,760	Majority: yes
(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.	86,552,927	308,582	272,913	--	0	Majority: yes
(iii) Non-binding advisory vote on the compensation of the Company's named executive officers.	59,168,689	1,808,669	73,304	--	26,083,760	Majority: yes
(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder.	46,645,607	14,304,810	100,245	--	26,083,760	Majority: yes

Source: Fate Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-15 — read the filing on EDGAR.

How asset managers voted at the Fate Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 140 asset managers that disclosed a Fate Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 59,168,689AGAINST: 1,808,669

Fate Therapeutics, Inc.’s own tally for this item (“(iii) Non-binding advisory vote on the compensation of the Company's named executive officers.”): 59,168,689 for, 1,808,669 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,272,513 outstanding shares: 50.9% for, 2% against (52.4% of the company cast a for/against vote).

The 139 asset managers below cast 98% of the shares they voted on this item FOR (52,833,651 for, 1,019,800 against).

FOR 98%

FOR: 52,833,651 (97.9%)AGAINST: 1,019,800 (1.9%)ABSTAIN: 4,500 (0.0%)NOT VOTED: 128,000 (0.2%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at Fate Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Redmile Group, LLC	12,872,946	0	For
Vanguard	9,068,847	5	For
BlackRock	8,383,463	194	For
ACADIAN ASSET MANAGEMENT LLC	3,029,747	51,458	For
GEODE CAPITAL MANAGEMENT, LLC	2,590,429	0	For
Fidelity	2,222,049	41,735	For
AQR	1,894,404	0	For
Charles Schwab	1,514,359	0	For
State Street	1,398,482	5,160	For
Invesco	1,149,915	0	For
Two Sigma	992,688	0	For
Irenic Capital Management LP	878,053	0	For
BRUCE FUND INC	789,188	0	For
DAFNA Capital Management LLC	550,000	0	For
Renaissance	518,788	0	For
Connor, Clark & Lunn Investment Management Ltd.	471,958	0	For
Northern Trust	4,108	465,793	Against
MELLON INVESTMENTS Corp	374,329	0	For
Dimensional	346,542	0	For
Nuveen	339,073	0	For
Citadel	324,943	0	For
Man Group plc	303,587	0	For
Equitable	299,868	0	For
Goldman Sachs	294,651	0	For
TIAA	271,483	0	For

Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.

2. Election of Class I Directors: Karin Jooss, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 59,655,584WITHHELD: 1,395,078

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Karin Jooss, Ph.D.”): 59,655,584 for, 1,395,078 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,272,513 outstanding shares: 51.3% for, 1% withheld (52.5% of the company cast a for/withheld vote).

The 43 asset managers below cast 100% of the shares they voted on this item FOR (18,800,389 for, 0 against).

FOR 99.3%

FOR: 18,800,389 (99.4%)ABSTAIN: 119,791 (0.6%)

Largest asset managers voting on “Election of Class I Directors: Karin Jooss, Ph.D.” at Fate Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,334,835	9,712	For
BlackRock	4,292,201	0	For
Fidelity	2,222,049	0	For
BRUCE FUND INC	789,188	0	For
Charles Schwab	756,976	0	For
Invesco	347,469	0	For
Equitable	190,328	109,540	For
TIAA	271,483	0	For
Dimensional	255,844	0	For
AQR	194,978	0	For
BRIDGEWAY FUNDS INC	185,000	0	For
QUANTITATIVE MASTER SERIES LLC	177,479	0	For
Goldman Sachs	166,654	0	For
Lincoln Financial	78,044	0	For
Northern Trust	61,862	0	For
MASTER INVESTMENT PORTFOLIO	58,263	0	For
Global X	51,084	0	For
Bridge Builder Trust	45,952	0	For
Pacific Life	43,851	0	For
Nationwide	35,680	0	For
Thrivent	33,153	0	For
Blackstone Alternative Investment Funds	25,500	0	For
Voya	22,502	0	For
SEI	18,600	0	For
ProShares	16,144	0	For

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

3. Election of Class I Directors: Laura J. Hamill

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 60,850,004WITHHELD: 200,658

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Laura J. Hamill”): 60,850,004 for, 200,658 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,272,513 outstanding shares: 52.3% for, 0.2% withheld (52.5% of the company cast a for/withheld vote).

The 43 asset managers below cast 100% of the shares they voted on this item FOR (18,920,180 for, 0 against).

FOR 100%

FOR: 18,920,180 (100.0%)

Largest asset managers voting on “Election of Class I Directors: Laura J. Hamill” at Fate Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	8,344,547	For
BlackRock	4,292,201	For
Fidelity	2,222,049	For
BRUCE FUND INC	789,188	For
Charles Schwab	756,976	For
Invesco	347,469	For
Equitable	299,868	For
TIAA	271,483	For
Dimensional	255,844	For
AQR	194,978	For
BRIDGEWAY FUNDS INC	185,000	For
QUANTITATIVE MASTER SERIES LLC	177,479	For
Goldman Sachs	166,654	For
Lincoln Financial	78,044	For
Northern Trust	61,862	For
MASTER INVESTMENT PORTFOLIO	58,263	For
Global X	51,084	For
Bridge Builder Trust	45,952	For
Pacific Life	43,851	For
Nationwide	35,680	For
Thrivent	33,153	For
Blackstone Alternative Investment Funds	25,500	For
Voya	22,502	For
SEI	18,600	For
ProShares	16,144	For

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

4. Election of Class I Directors: Robert S. Epstein, M.D., M.S.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 59,332,820WITHHELD: 1,717,842

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Robert S. Epstein, M.D., M.S.”): 59,332,820 for, 1,717,842 withheld, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,272,513 outstanding shares: 51.0% for, 1% withheld (52.5% of the company cast a for/withheld vote).

The 43 asset managers below cast 100% of the shares they voted on this item FOR (18,558,811 for, 0 against).

FOR 98%

FOR: 18,558,811 (98.1%)ABSTAIN: 361,369 (1.9%)

Largest asset managers voting on “Election of Class I Directors: Robert S. Epstein, M.D., M.S.” at Fate Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,330,131	14,416	For
BlackRock	4,292,201	0	For
Fidelity	2,222,049	0	For
BRUCE FUND INC	789,188	0	For
Charles Schwab	756,976	0	For
Invesco	347,469	0	For
Equitable	190,328	109,540	For
TIAA	271,483	0	For
Dimensional	255,844	0	For
AQR	194,978	0	For
BRIDGEWAY FUNDS INC	185,000	0	For
QUANTITATIVE MASTER SERIES LLC	177,479	0	For
Goldman Sachs	0	166,654	Abstain
Lincoln Financial	78,044	0	For
Northern Trust	0	61,862	Abstain
MASTER INVESTMENT PORTFOLIO	58,263	0	For
Global X	51,084	0	For
Bridge Builder Trust	45,952	0	For
Pacific Life	43,851	0	For
Nationwide	35,680	0	For
Thrivent	33,153	0	For
Blackstone Alternative Investment Funds	25,500	0	For
Voya	22,502	0	For
SEI	18,600	0	For
ProShares	16,144	0	For

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

5. TO APPROVE A PROPOSAL TO AMEND AND RESTATE THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER.

COMPENSATIONMajority of the votes cast: yes

77% Majority: yes · of votes cast

FOR 77%AGAINST 23%

FOR: 46,645,607AGAINST: 14,304,810

Fate Therapeutics, Inc.’s own tally for this item (“(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder.”): 46,645,607 for, 14,304,810 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,272,513 outstanding shares: 40% for, 12% against (52.4% of the company cast a for/against vote).

The 43 asset managers below cast 90% of the shares they voted on this item FOR (17,025,443 for, 1,894,736 against).

FOR 90%10%

FOR: 17,025,443 (90.0%)AGAINST: 1,894,736 (10.0%)

Largest asset managers voting on “TO APPROVE A PROPOSAL TO AMEND AND RESTATE THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE ” at Fate Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	8,334,784	9,762	For
BlackRock	4,292,201	0	For
Fidelity	2,222,049	0	For
BRUCE FUND INC	789,188	0	For
Charles Schwab	756,976	0	For
Invesco	0	347,469	Against
Equitable	190,328	109,540	For
TIAA	0	271,483	Against
Dimensional	0	255,844	Against
AQR	0	194,978	Against
BRIDGEWAY FUNDS INC	0	185,000	Against
QUANTITATIVE MASTER SERIES LLC	177,479	0	For
Goldman Sachs	0	166,654	Against
Lincoln Financial	0	78,044	Against
Northern Trust	0	61,862	Against
MASTER INVESTMENT PORTFOLIO	58,263	0	For
Global X	51,084	0	For
Bridge Builder Trust	45,952	0	For
Pacific Life	43,851	0	For
Nationwide	35,680	0	For
Thrivent	0	33,153	Against
Blackstone Alternative Investment Funds	0	25,500	Against
Voya	0	22,502	Against
SEI	18,600	0	For
ProShares	0	16,144	Against

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

6. TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 86,552,927AGAINST: 308,582

Fate Therapeutics, Inc.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 86,552,927 for, 308,582 against, per its Form 8-K filed 2026-06-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 116,272,513 outstanding shares: 74% for, 0.3% against (75% of the company cast a for/against vote).

The 43 asset managers below cast 100% of the shares they voted on this item FOR (18,920,180 for, 0 against).

FOR 100%

FOR: 18,920,180 (100.0%)

Largest asset managers voting on “TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE C” at Fate Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	8,344,547	For
BlackRock	4,292,201	For
Fidelity	2,222,049	For
BRUCE FUND INC	789,188	For
Charles Schwab	756,976	For
Invesco	347,469	For
Equitable	299,868	For
TIAA	271,483	For
Dimensional	255,844	For
AQR	194,978	For
BRIDGEWAY FUNDS INC	185,000	For
QUANTITATIVE MASTER SERIES LLC	177,479	For
Goldman Sachs	166,654	For
Lincoln Financial	78,044	For
Northern Trust	61,862	For
MASTER INVESTMENT PORTFOLIO	58,263	For
Global X	51,084	For
Bridge Builder Trust	45,952	For
Pacific Life	43,851	For
Nationwide	35,680	For
Thrivent	33,153	For
Blackstone Alternative Investment Funds	25,500	For
Voya	22,502	For
SEI	18,600	For
ProShares	16,144	For

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Largest Fate Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Fate Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 116,272,513 shares outstanding at the time of that meeting.

Top Fate Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Redmile Group, LLC	11.07%
2	Vanguard	7.80%
3	BlackRock	7.21%
4	ACADIAN ASSET MANAGEMENT LLC	2.65%
5	GEODE CAPITAL MANAGEMENT, LLC	2.23%
6	Fidelity	1.95%
7	AQR	1.63%
8	Charles Schwab	1.30%
9	State Street	1.21%
10	Invesco	0.99%

Reported Fate Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Fate Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Redmile Group, LLC	15.68%	13D
Entities affiliated with Redmile Group, LLC	11.07%	DEF14A
ARK Investment Management LLC	8.87%	DEF14A
BlackRock	8.66%	13F
Vanguard Group	7.72%	13F
Two Sigma	2.98%	13F
AQR Capital	2.58%	13F
Renaissance Technologies	2.56%	13F
Geode Capital	2.23%	13F
State Street	1.95%	13F

Percentages above are of 116,272,513 shares outstanding, as reported by Fate Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Fate Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Fate Therapeutics, Inc.'s shareholder meeting held 2026-06-12, in the 2025-2026 proxy season, 140 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 900 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Fate Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-15.

Fate Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).